Specializing in large-scale hiPSC projects.
The Paul Burridge Lab
The Burridge lab works in the field of pharmacogenomics (precision medicine), cardio-oncology, cardiovascular disease modeling, regenerative medicine, cancer, and cultivated meat, using induced pluripotent stem cells (iPSCs) as our model. We specialize in large-scale hiPSC projects that required reprogramming, sequencing, editing, differentiating and phenotyping hundreds of hiPSC lines.
We are responsible for a number of firsts including: the first directed cardiac differentiation protocol (Burridge et al., 2006), the first non-integrating reprogramming of blood to iPSC (Burridge et al., 2011), the first chemically defined differentiation protocol (Burridge et al., 2014), the first demonstration that doxorubicin-induced cardiotoxicity is a genomic disease (Burridge et al., 2016), the first cost-effective method of culturing iPSC (Kuo et al., 2020), and most recently, the genomic basis of predispostion to doxorubicin-induced cardiotoxicity (Magdy et al., 2021 and 2022).
Our research program is focused on using induced pluripotent stem cells (iPSC) in pharmacogenomics, disease modeling and regenerative medicine. Applying a combination of hiPSC culture, tissue engineering, sequencing, high-throughput assays and drug screens, we can establish the genetic cause of a patient's specific drug response and use this information to discover new drugs.